Appili Therapeutics Inc is a Canada-based anti-infective pharmaceutical development company. The Company focuses on identifying, acquiring and advancing therapeutics for infectious disease. The Company is engaged in developing strategies to develop new classes of antibiotics and anti-infectives to the clinic to improve treatment and health of patients suffering from infection. The Company has over two anti-infective programs, which include ATI-1501 and ATI-1503. The Company's ATI-1501 is a taste-masked treatment for clostridium difficile infection. The Company's ATI-1503 is an antibiotic with a potential to treat Gram-negative infections, such as Klebsiella pneumoniae. The Company’s agents focus on the therapeutics, including antivirals, antifungals, antiparasitics and antimicrobials, which can treat the hospital and community acquired infections caused by multi-drug resistant pathogens.